Turkey OTC Regulations Must Meet Stakeholders’ Needs – Trade Group
This article was originally published in The Tan Sheet
Turkey’s reimbursed OTC market has reached around TRY2.5 billion ($1.19 billion). As the rapidly growing sector attracts pharmaceutical companies, its development also complicates discussions about enacting legislation for OTCs. In an interview with Informa Business Information’s PharmAsia News, Osman Kara of the Association of Research Based Pharmaceutical Companies (AIFD) calls for legislation that addresses the concerns of all stakeholders.